Quantum-Si incorporated (QSI)
| Market Cap | 197.80M -7.7% |
| Revenue (ttm) | 2.44M -20.3% |
| Net Income | -101.34M |
| EPS | -0.51 |
| Shares Out | 216.37M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,548,907 |
| Open | 0.8900 |
| Previous Close | 0.9003 |
| Day's Range | 0.8853 - 0.9400 |
| 52-Week Range | 0.6912 - 3.1000 |
| Beta | 3.09 |
| Analysts | Buy |
| Price Target | 1.00 (+9.39%) |
| Earnings Date | May 7, 2026 |
About QSI
Quantum-Si incorporated, a life sciences company, develops proprietary, universal, and single-molecule detection platform applied to proteomics to enable next-gen protein sequencing (NGPS). The company offers Platinum and Platinum Pro NGPS instruments for single-molecule, amino acid level resolution, and automated data analysis; library preparation kits to prepare a customer’s protein sample for sequencing; and sequencing kits, which contain the reagents and consumables used to perform NGPS. It also provides Platinum analysis software, a cloud-... [Read more]
Financial Performance
In 2025, Quantum-Si incorporated's revenue was $2.44 million, a decrease of -20.34% compared to the previous year's $3.06 million. Losses were -$101.34 million, 0.33% more than in 2024.
Financial StatementsAnalyst Summary
According to 2 analysts, the average rating for QSI stock is "Buy." The 12-month stock price target is $1.0, which is an increase of 9.39% from the latest price.
News
Quantum-Si to Report First Quarter 2026 Financial Results on May 7, 2026
BRANFORD, Conn.--(BUSINESS WIRE)--Quantum-Si to Report First Quarter 2026 Financial Results on May 7, 2026.
Quantum-Si Announces Two Customer Posters to be Presented at the American Association of Cancer Research Annual Meeting
BRANFORD, Conn.--(BUSINESS WIRE)--Quantum-Si Announces Two Customer Posters to be Presented at the American Association of Cancer Research Annual Meeting.
Quantum-Si Announces New Manuscript Demonstrating the Value of Single-molecule Protein Sequencing to Aid in Identifying New Cancer Treatment Strategies
BRANFORD, Conn.--(BUSINESS WIRE)--Quantum-Si Announces New Manuscript Demonstrating Value of Single-molecule Protein Sequencing to Aid in Identifying New Cancer Treatment Strategies.
Quantum-Si Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BRANFORD, Conn.--(BUSINESS WIRE)--Quantum-Si Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4).
Quantum-Si Announces First Customer Samples Tested on the Proteus™ Prototype System
BRANFORD, Conn.--(BUSINESS WIRE)--Quantum-Si Announces First Customer Samples Tested on the Proteus™ Prototype System.
Quantum-Si Announces the Start of the Proteus™ Roadshow
BRANFORD, Conn.--(BUSINESS WIRE)--Quantum-Si Announces the Start of the Proteus™ Roadshow.
Quantum-Si Shares Slip After Q4 Revenue Miss
Quantum-Si, Inc. (NASDAQ: QSI) shares moved lower in Tuesday's extended trading after the company released its fourth-quarter earnings report, missing Street revenue estimates.
Quantum-Si incorporated Earnings Call Transcript: Q4 2025
2026 will be a transition year with revenue mainly from consumables, limited new instrument sales, and a focus on preparing for the Proteus launch. Financial discipline is maintained, with strong cash reserves and lower gross margins expected due to revenue mix.
Quantum-Si Reports Fourth Quarter and Full Year 2025 Financial Results
BRANFORD, Conn.--(BUSINESS WIRE)--Quantum-Si Reports Fourth Quarter and Full Year 2025 Financial Results.
Quantum-Si to Report Fourth Quarter and Full Year 2025 Financial Results on March 3, 2026
BRANFORD, Conn.--(BUSINESS WIRE)--Quantum-Si to Report Fourth Quarter and Full Year 2025 Financial Results on March 3, 2026.
Quantum-Si Announces the Release of Two New Manuscripts Demonstrating the Value of Single-Molecule Protein Sequencing in Clinical Proteomics and Pathogen & Toxin Detection
BRANFORD, Conn.--(BUSINESS WIRE)--Quantum-Si Announces the Release of Two New Manuscripts.
Quantum-Si Announces Launch of New Version 3 Library Preparation Kit and a Suite of Data Analysis Tool Enhancements
BRANFORD, Conn.--(BUSINESS WIRE)--Quantum-Si Announces Launch of New Version 3 Library Preparation Kit and a Suite of Data Analysis Tool Enhancements.
Quantum-Si incorporated Transcript: CG MedTech, Diagnostics and Digital Health & Services Forum
Proteus, a next-generation protein sequencing platform, is on track for a 2026 launch, offering major architectural advances for scalability and cost efficiency. Early data show performance exceeding current systems, with commercialization strategies and financial resources in place to support growth.
Quantum-Si Highlights Significant Development Advancements for Proteus™ and Industry Leading Technology Pipeline at Investor & Analyst Day
BRANFORD, Conn.--(BUSINESS WIRE)--Quantum-Si Highlights Significant Development Advancements for ProteusTM and Industry Leading Technology Pipeline at Investor & Analyst Day.
Quantum-Si incorporated Transcript: Investor Day 2025
Proteus introduces a scalable, automated protein sequencing platform with a roadmap to detect all 20 amino acids and broad PTM coverage by 2027. The system targets high-value applications, offers lower cost and higher throughput, and is set for commercial launch at the end of 2026, with early access and upgrade programs planned.
Quantum-Si to Highlight Significant Proteus™ Platform Development Progress and Provide Insights into the Company's Industry Leading Technology Pipeline at Investor & Analyst Day
BRANFORD, Conn.--(BUSINESS WIRE)--QSI to Highlight Significant Proteus™ Platform Dev Progress & Provide Insights into Company's Industry Leading Tech Pipeline at Investor & Analyst Day.
Quantum-Si incorporated Earnings Call Transcript: Q3 2025
Q3 2025 revenue was $552,000, with gross margin at 35% and continued capital market headwinds, especially in academia. Strategic placements expanded the install base, and the Proteus platform reached a key prototype milestone. Cash and investments stood at $230.5 million.
Quantum-Si Reports Third Quarter 2025 Financial Results
BRANFORD, Conn.--(BUSINESS WIRE)--Quantum-Si Reports Third Quarter 2025 Financial Results. Announces Successful Sequencing on Prototype Proteus Unit, Development Program is On-Track.
Quantum-Si to Participate in the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum
BRANFORD, Conn.--(BUSINESS WIRE)--Quantum-Si to Participate in the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum.
Quantum-Si to Report Third Quarter 2025 Financial Results on November 5, 2025
BRANFORD, Conn.--(BUSINESS WIRE)--Quantum-Si to Report Third Quarter 2025 Financial Results on November 5, 2025.
Quantum-Si to Host Investor & Analyst Event in New York City on November 19, 2025
BRANFORD, Conn--(BUSINESS WIRE)--Quantum-Si to Host Investor & Analyst Event in New York City on November 19, 2025.
Quantum-Si incorporated Transcript: H.C. Wainwright 27th Annual Global Investment Conference
The event highlighted progress on the Proteus platform, targeting a prototype by year-end and commercial launch next year. Market expansion into biopharma and government sectors, ongoing product and software innovation, and a strong financial position with disciplined spending were emphasized.
Quantum-Si Announces the Launch of V4 Sequencing Kit, Expanding Proteome Coverage and Unlocking New Applications for Protein Sequencing
BRANFORD, Conn.--(BUSINESS WIRE)--Quantum-Si Announces the Launch of V4 Sequencing Kit, Expanding Proteome Coverage and Unlocking New Applications for Protein Sequencing.
Quantum-Si to Participate in the H.C. Wainwright 27th Annual Global Investment Conference
BRANFORD, Conn.--(BUSINESS WIRE)--Quantum-Si to Participate in the H.C. Wainwright 27th Annual Global Investment Conference.
Quantum-Si incorporated Transcript: UBS Precision Medicine Frontiers Summit Conference
Panelists highlighted breakthroughs in proteomics and flow cytometry, enabling new research and clinical applications. Strategic adoption, robust pipelines, and AI integration are driving growth despite market challenges, with next-gen platforms and global clinical expansion underway.